Critical Reviews in Oncology / Hematology
Volume 74, Issue 3 , Pages 203-210 , June 2010

Pegfilgrastim primary prophylaxis vs. current practice neutropenia management in elderly breast cancer patients receiving chemotherapy

  • Matti Aapro

      Affiliations

    • Institut Multidisciplinaire d’Oncologie (IMO), Clinique de Genolier, 1 Route du Muids, 1272 Genolier, Switzerland
    • Corresponding Author InformationCorresponding author. Tel.: +41 22 366 91 06; fax: +41 22 366 91 31.
    • ,
  • Matthias Schwenkglenks

      Affiliations

    • European Center of Pharmaceutical Medicine, University of Basel, Basel, Switzerland
    • ,
  • Gary H. Lyman

      Affiliations

    • Duke University Medical Center, Durham, NC, United States
    • ,
  • Antonio Lopez Pousa

      Affiliations

    • Medical Oncology, Hospital de Sant Pau, Barcelona, Spain
    • ,
  • Susan Lawrinson

      Affiliations

    • Biostatistics, Amgen Ltd, Uxbridge, United Kingdom
    • ,
  • Tomas Skacel

      Affiliations

    • Clinical Development, Amgen (Europe) GmbH, Zug, Switzerland
    • Internal Medicine – Hematoonkology, University Hospital, Brno, Czech Republic
    • ,
  • Pamela Bacon

      Affiliations

    • Clinical Development, Amgen (Europe) GmbH, Zug, Switzerland
    • ,
  • Gunter von Minckwitz

      Affiliations

    • German Breast Group, GBG Forschungs GmbH, University of Frankfurt, Frankfurt, Germany

,Accepted 18 June 2009.

References 

  1. Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106:2258–2266
  2. Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007;25:3158–3167
  3. Bonadonna G, Moliterni A, Zambetti M, et al. 30 years’ follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ. 2005;330:217
  4. Chirivella I, Bermejo B, Insa A, et al. Impact of chemotherapy dose-related factors on survival in breast cancer patients treated with adjuvant anthracycline-based chemotherapy. J Clin Oncol. 2006;18S:668;[Abstract]
  5. Szutowicz E, Radecka B, Dziadziuszko R, Jassem J. Relative dose intensity (RDI) relevance in adjuvant CMF chemotherapy of breast cancer. Eur J Cancer Suppl. 2006;4:155;[Abstract 366]
  6. Aapro MS, Cameron DA, Pettengell R, et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer. 2006;42:2433–2453
  7. Hryniuk W, Frei E, Wright FA. A single scale for comparing dose-intensity of all chemotherapy regimens in breast cancer: summation dose-intensity. J Clin Oncol. 1998;16:3137–3147
  8. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24:3187–3205
  9. National Comprehensive Cancer Network . NCCN clinical practice guidelines in oncology™. Myeloid growth factors. Jamestown, PA: National Comprehensive Cancer Network; 2008;
  10. Greil R, Psenak O. Hematopoietic growth factors: ESMO recommendations for the application. Ann Oncol. 2007;18(Suppl. 2):ii89–ii91
  11. Gridelli C, Aapro MS, Barni S, et al. Role of colony stimulating factors (CSFs) in solid tumours: results of an expert panel. Crit Rev Oncol Hematol. 2007;63:53–64
  12. Zielinski CC, Awada A, Cameron DA, Cufer T, Martin M, Aapro M. The impact of new European Organisation for Research and Treatment of Cancer guidelines on the use of granulocyte colony-stimulating factor on the management of breast cancer patients. Eur J Cancer. 2008;44:353–365
  13. Muss HB, Berry DA, Cirrincione C, et al. Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience. J Clin Oncol. 2007;25:3699–3704
  14. Crivellari D, Bonetti M, Castiglione-Gertsch M, et al. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII. J Clin Oncol. 2000;18:1412–1422
  15. Du XL, Osborne C, Goodwin JS. Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer. J Clin Oncol. 2002;20:4636–4642
  16. Muss HB, Woolf S, Berry D, et al. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA. 2005;293:1073–1081
  17. Repetto L, Biganzoli L, Koehne CH, et al. EORTC cancer in the elderly task force guidelines for the use of colony-stimulating factors in elderly patients with cancer. Eur J Cancer. 2003;39:2264–2272
  18. Bokemeyer C, Honecker F, Wedding U, Spath-Schwalbe E, Lipp HP, Kolb G. Use of hematopoietic growth factors in elderly patients receiving cytotoxic chemotherapy. Onkologie. 2002;25:32–39
  19. Crivellari D, Aapro M, Leonard R, et al. Breast cancer in the elderly. J Clin Oncol. 2007;25:1882–1890
  20. Wildiers H, Kunkler I, Biganzoli L, et al. Management of breast cancer in the elderly: recommendations of the International Society of Geriatric Oncology (SIOG). Lancet Oncol. 2007;8:1101–1115
  21. von Minckwitz G, Schwenkglenks M, Skacel T, et al. Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropenia management: results from an integrated analysis. Eur J Cancer. 2009;45:608–617
  22. Schwenkglenks M, Jackisch C, Constenla M, et al. Neutropenic event risk and impaired chemotherapy delivery in six European audits of breast cancer treatment. Support Care Cancer. 2006;14:901–909
  23. von Minckwitz G, Kummel S, du BA, et al. Pegfilgrastim +/− ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. Ann Oncol. 2008;19:292–298
  24. Vogel CL, Wojtukiewicz MZ, Carroll RR, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol. 2005;23:1178–1184
  25. Romieu G, Clemens M, Mahlberg R, et al. Pegfilgrastim supports delivery of FEC-100 chemotherapy in elderly patients with high risk breast cancer: a randomized phase 2 trial. Crit Rev Oncol Hematol. 2007;64:64–72
  26. Lichtman SM, Wildiers H, Launay-Vacher V, Steer C, Chatelut E, Aapro M. International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer. 2007;43:14–34
  27. Lichtman SM, Wildiers H, Chatelut E, et al. International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients—an analysis of the medical literature. J Clin Oncol. 2007;25:1832–1843
  28. Shayne M, Culakova E, Poniewierski MS, et al. Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy. Cancer. 2007;110:1611–1620
  29. Shayne M, Crawford J, Dale DC, Culakova E, Lyman GH. Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy. Breast Cancer Res Treat. 2006;100:255–262
  30. Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol. 2003;21:4524–4531
  31. Lyman GH, Lyman CH, Agboola O. Risk models for predicting chemotherapy-induced neutropenia. Oncologist. 2005;10:427–437
  32. Loibl S, von Minckwitz G, Harbeck N, et al. Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials. Breast Cancer Res. 2008;10:R77;[Epub ahead of print]
  33. Crawford J, Dale DC, Kuderer NM, et al. Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Natl Compr Canc Netw. 2008;6:109–118
  34. Pinto L, Liu Z, Doan Q, Bernal M, Dubois R, Lyman G. Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials. Curr Med Res Opin. 2007;23:2283–2295
  35. Green MD, Koebl H, Baselga J, et al. A randomized double-blind multicenter phase III study of fixed-dose single administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol. 2003;14:29–35

PII: S1040-8428(09)00124-3

doi: 10.1016/j.critrevonc.2009.06.004

Critical Reviews in Oncology / Hematology
Volume 74, Issue 3 , Pages 203-210 , June 2010

Article Tools

* Image Usage & Resolution